drugset
Drugs / RSVPreF3 OA
last change May 2026 re-read 2 minutes ago

RSVPreF3 OA

also known as adjuvanted RSVPreF3 · GSK3844766A · Respiratory Syncytial Virus PreFusion protein 3 Older Adults vaccine · RSVPreF3 · RSVPreF3 OA investigational vaccine

Vaccine

Developed for
respiratory syncytial virus infectious disease
Investigated by
GlaxoSmithKline

Trials 13 · a red edge is where a trial was stopped

today NCT06614725 · Ph 3 NCT06551181 · Ph 3 NCT06389487 · Ph 3 NCT06374394 · Ph 3 NCT05966090 · Ph 3 NCT05921903 · Ph 2 NCT05879107 · Ph 3 NCT05590403 · Ph 3 NCT05559476 · Ph 3 NCT05059301 · Ph 3 NCT04886596 · Ph 3 NCT04732871 · Ph 3 NCT04657198 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT05921903 Jul 2023 → Jun 2024 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT04657198 Dec 2020 → Jun 2021 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 311 trials
Phase 3 NCT06614725 Oct 2024 → Jun 2025 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT06551181 Aug 2024 → Apr 2025 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT06389487 Apr → Jul 2024 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT06374394 Apr → Nov 2024 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT05966090 Jul 2023 → Feb 2024 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT05879107 May → Dec 2023 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT05590403 Oct 2022 → Mar 2023 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT05559476 Oct 2022 → Mar 2023 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT05059301 Oct 2021 → Jan 2022 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT04886596 May 2021 → Apr 2022 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

FieldValueCited text
Known as RSVPreF3 OA ClinicalTrials.gov intervention name — accepted as the source's own label NCT06614725 ↗
11

NCT05590403 ↗

NCT05966090 ↗

NCT04732871 ↗

NCT05921903 ↗

NCT06374394 ↗

NCT06551181 ↗

NCT06389487 ↗

NCT05059301 ↗

NCT05879107 ↗

NCT04657198 ↗

NCT04886596 ↗
Known as adjuvanted RSVPreF3 “the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) was immunologically non-inferior at 1 month post-vaccination in...” PMID 41194599 ↗ Nov 2025
1

“Co-administration of AS01E-adjuvanted respiratory syncytial virus vaccine (adjuvanted RSVPreF3)” PMID 42054374 ↗ Apr 2026
Known as GSK3844766A “RSVPreF3 OA investigational vaccine (GSK3844766A)” NCT04657198 ↗
Known as Respiratory Syncytial Virus PreFusion protein 3 Older Adults vaccine “Respiratory Syncytial Virus PreFusion protein 3 Older Adults vaccine” NCT05966090 ↗
Known as RSVPreF3 “The AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) is approved for ≥60-year-olds and 50-59-year-olds at increased...” PMID 41757519 ↗ May 2026
Known as RSVPreF3 OA investigational vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05559476 ↗
Modality Vaccine “adjuvanted vaccine against RSV” PMID 37699064 ↗ Feb 2024
Route Intramuscular “RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm” NCT04657198 ↗